Furthermore, SLE patients treated with anti-IFNγ monoclonal antibody AMG 811 showed reduced serum levels of IP-10 and less adverse events as compared with those in SLE patients treated with placebo (138, 139). The gene discussed is CXCL10; the disease is systemic lupus erythematosus.